Related Experiment Video
Updated: May 23, 2026

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport
Published on: November 27, 2016
Investigational ABC transporter inhibitors
Marco Falasca1, Kenneth J Linton
1Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, Centre for Diabetes, Inositide Signalling Group, 4 Newark Street, London, UK. m.falasca@qmul.ac.uk
Introduction:
Multidrug resistance (MDR) is the main cause of failure in cancer therapy. One mechanism responsible for MDR is the active efflux of drugs by ATP-binding cassette (ABC) transporters. Several agents have been developed to block transporter-mediated drug efflux and some of these compounds have entered Phase II/III clinical testing. Evidence is also emerging of the role played by ABC transporters in cancer cell signalling that is likely to be important in disease progression and which is distinct from MDR.
Areas Covered:
This article reviews current literature to analyse the rationale for targeting ABC transporters in cancer. Preclinical and clinical results of ABC transporter inhibitors in early clinical trials, as single agents or in combination with other drugs, are described. The development of new strategies to target MDR and the emerging roles of ABC transporters in cancer signalling are discussed.
Expert Opinion:
The intense active search for safe and effective inhibitors of ABC transporters has led to some success in MDR reversal in preclinical studies. However, there has been little impact on clinical outcome. The discovery of novel, potent and nontoxic inhibitors as well as new treatment strategies is therefore needed.
Insights
Targeting ATP-binding cassette (ABC) transporters can reverse multidrug resistance (MDR) in preclinical cancer studies. However, clinical outcomes remain limited, necessitating novel inhibitors and strategies for effective cancer therapy.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Multidrug resistance (MDR) significantly hinders cancer therapy success.
- ATP-binding cassette (ABC) transporters actively efflux chemotherapy drugs, contributing to MDR.
- Emerging evidence implicates ABC transporters in cancer cell signaling pathways beyond drug resistance.
Purpose of the Study:
- To review the rationale for targeting ABC transporters in cancer treatment.
- To analyze preclinical and clinical data of ABC transporter inhibitors.
- To discuss novel strategies for overcoming MDR and the role of ABC transporters in cancer signaling.
Main Methods:
- Literature review of current research on ABC transporters in cancer.
- Analysis of preclinical and clinical trial results for ABC transporter inhibitors.
- Discussion of emerging therapeutic strategies and signaling roles.
Main Results:
- Preclinical studies show success in reversing MDR using ABC transporter inhibitors.
- Clinical trials have demonstrated limited impact on patient outcomes to date.
- ABC transporters play roles in cancer progression distinct from MDR.
Conclusions:
- Developing safe and effective ABC transporter inhibitors is crucial for improving cancer treatment.
- Current inhibitors have shown limited clinical efficacy, highlighting the need for new approaches.
- Further research into novel inhibitors and therapeutic strategies targeting ABC transporters is essential.
Related Concept Videos
ABC Transporters: Exporter
ABC Transporters: Importer
In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types:
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Carrier-Mediated Transport
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Hepatic Drug Clearance: Role of Transporters
Methods for Studying Drug Absorption: In vitro
The diffusion cell method uses a two-compartment cell, including a donor compartment with the drug solution, which simulates the environment where the drug is applied, and a receptor compartment with a buffer solution, which simulates the environment...

![Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-7941](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F59557.jpg&w=3840&q=50)